| Market Cap | 8.27B |
| Revenue (ttm) | 562.12M |
| Net Income (ttm) | -155.73M |
| Shares Out | 64.67M |
| EPS (ttm) | -2.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,067,525 |
| Open | 128.07 |
| Previous Close | 127.90 |
| Day's Range | 127.77 - 128.07 |
| 52-Week Range | 73.04 - 128.24 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 129.12 (+0.99%) |
| Earnings Date | Jul 31, 2025 |
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul... [Read more]
Financial Performance
In 2024, Blueprint Medicines's revenue was $508.82 million, an increase of 104.04% compared to the previous year's $249.38 million. Losses were -$67.09 million, -86.77% less than in 2023.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $129.12, which is an increase of 0.99% from the latest price.
News
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar...
Sanofi-Blueprint deal is a bullish signal about biotech M&A
The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. San...
Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
The deal announced Monday is Sanofi's third of the year so far.
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio PARIS and CAMBRIDGE, Mass. , June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medi...
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies s...
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery
NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license agreem...
Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communica...
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 -- -- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 -...
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth
Blueprint Medicines' focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other promi...
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. , March 31, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annua...
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress
-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of t...
Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Cassie Saitow - Director, Investor Relations Kate Haviland - President...
Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results
-- Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approxim...
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
-- Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates -- -- Expect to achieve $2 b...
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 ...
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modif...
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion int...
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief E...